IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine CarcinomasPRNewsWire · 1 day ago
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal MelanomaPRNewsWire · 5 days ago
IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in StockDefense World · Oct 11, 2026
IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What HappenedDefense World · Sep 30, 2026
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and DevelopmentPRNewsWire · Sep 28, 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PRNewsWire · Sep 25, 2026IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$1.06 | -$1.22 | Miss |
| May 5, 2026 | -$1.07 | -$1.11 | Miss |
| Feb 17, 2026 | -$0.95 | -$0.94 | Beat |
| Nov 4, 2025 | -$0.95 | $1.33 | Beat |
| Aug 5, 2025 | -$0.85 | -$0.88 | Miss |
| May 6, 2025 | -$0.75 | -$0.82 | Miss |